相关实验视频

Updated: Jan 14, 2026

Depletion and Reconstitution of Macrophages in Mice

Depletion and Reconstitution of Macrophages in Mice

Published on: August 1, 2012

一个级联向系统,将多醇输送到M1巨的线粒体中,用于炎症性肠病治疗

Xin Liu¹, Xin Wang¹, Zongxin Yue¹

¹Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198, China.

Advanced healthcare materials

|October 27, 2025

概括

一种新的药物输送系统精确地准了炎症性肠病 (IBD) 中的巨细胞线粒体. 这种系统增强了氨酸的输送,提供了一个有前途的新疗法策略,提高了疗效和减少了副作用.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
免疫学免疫学免疫学

背景情况:

目前的炎症性肠病 (IBD) 治疗面临的挑战是有效性有限,副作用显著.
向巨细胞线粒体为IBD提供了一个有希望的治疗途径.
开发精确的药物输送系统对于有效的IBD管理至关重要.

研究的目的:

设计一个级联向系统 (HP-mExo/TP@Qu或HET@Qu) 以有针对性的向肠道M1巨线粒体输送素 (Qu).
开发以酸 (TA) 为基础的线粒体向小粒体 (TP@Qu) 作为功能载体.
在IBD动物模型中评估HET@Qu的治疗疗效.

主要方法:

制造一个双向系统,包括一个CD44向外 (HP-mExo) 和一个线粒体向核心 (TP@Qu).
利用酸用于构建针对线粒体的菌体.
在IBD动物模型中对HET@Qu的体内评估,评估炎症标志物,肠道屏障功能,巨分化和肠道微生物群.

主要成果:

HET@Qu成功地将氨酸输送到巨细胞的线粒体中.
在IBD动物模型中证明了显著的治疗疗效.
减弱了炎症级联,恢复了肠道屏障功能,促进了M2巨细胞两极分化,并重新平衡了肠道微生物群.

结论:

该HET@Qu系统有效地克服了向目标站点输送Quercetin的挑战.
这种双重准策略为炎症性肠病提供了一个新的,精确的治疗选择.
利用像酸这样的天然产品是创造功能性纳米医学载体的可行途径.

关键词:

级联准定位是指级联准的目标.外基因组是外基因组的组成部分.炎症性肠病是一种炎症性肠病.针对线粒体的目标

更多相关视频

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells

Published on: October 17, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...